VELETRI Market Research Reveals Path To $2.07 Billion By 2030

The Veletri market has witnessed significant growth recently, driven by advances in treatment options for pulmonary arterial hypertension (PAH) and increasing patient diagnoses. As awareness and medical infrastructure improve, the market is poised for continued expansion in the years ahead. This overview explores the current market size, leading players, emerging trends, and key segments shaping the Veletri landscape.

Veletri Market Size and Projected Growth Through 2030
The Veletri market has experienced robust growth, with its size rising from $1.45 billion in 2025 to an anticipated $1.56 billion in 2026, reflecting a compound annual growth rate (CAGR) of 7.7%. This expansion during the historical period is largely driven by the clinical effectiveness of epoprostenol, an increase in PAH diagnoses, hospitals relying heavily on intravenous prostacyclins, the scarcity of oral alternatives, and improving survival rates for PAH patients. Looking ahead, the market is set to expand further, reaching $2.07 billion by 2030 at a CAGR of 7.4%. Factors fueling this growth include a rising prevalence of PAH, the development of specialty PAH treatment centers, growing demand for stable drug formulations, wider adoption of infusion therapies, and heightened awareness regarding PAH management. Key trends expected to influence the market involve a shift toward non-refrigerated prostacyclin therapies, increased use of continuous infusion treatments, demand for advanced PAH vasodilators, hospital-based management growth, and an emphasis on enhancing patient mobility.

Download a free sample of the veletri market report:
https://thebusinessresearchcompany.com/sample_request?id=92425415&type=smp&name=VELETRI%20Market%20Report%202026&utm_source=OpenPR&utm_medium=Paid&utm_campaign=Oct_PR

Key Players Driving the Veletri Market Forward
Several established pharmaceutical companies play a dominant role in the Veletri market. These include Johnson & Johnson, Bayer Pharma AG, Novartis AG, GlaxoSmithKline plc, Gilead Sciences Inc., Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim International GmbH, Sandoz International GmbH, Sun United Therapeutics Corporation, Actelion Pharmaceuticals Ltd., Pfizer Inc., Euroapi S.A., Sai Life Sciences Limited, Zhejiang Ausun Pharmaceutical Co. Ltd., Yonsung Fine Chemicals Co. Ltd., Cayman Pharma S.r.o., Nichi-Iko Pharmaceutical Co. Ltd., Dr. Reddy's Laboratories Ltd., Aurobindo Pharma Ltd., and Hikma Pharmaceuticals plc. These companies contribute significantly to product development, market penetration, and therapeutic advancements within the PAH treatment space.

Emerging Trends Shaping the Future of the Veletri Market
A major focus among leading firms is on expanding accessibility through generic versions of Veletri, such as FDA-approved epoprostenol sodium injections. These generics provide cost-effective alternatives that maintain the same quality, safety, and efficacy as branded products, helping broaden treatment options for PAH patients. For example, in October 2025, Mylan Pharmaceuticals of the United States received FDA approval for its generic Veletri injection, available in multiple vial strengths including 20 mg/20 mL, 50 mg/20 mL, 100 mg/20 mL, and 200 mg/20 mL. This generic maintains the prostacyclin mimetic activity critical to improving exercise tolerance and symptom management in pulmonary arterial hypertension, making it an important development for patient care and market growth.

View the full veletri market report:
https://www.thebusinessresearchcompany.com/report/veletri-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Oct_PR

Categories and Segments Defining the Veletri Market
The Veletri market report categorizes the industry into several critical segments. By formulation stability, it divides into room-temperature stable formulations and refrigeration-required formulations. Treatment settings include hospitals and specialized pulmonary hypertension centers, while distribution channels comprise hospital pharmacies and specialty pharmacies. Further breakdown includes subsegments such as ready-to-use and extended stability infusion solutions under room-temperature stable formulations, as well as reconstituted cold-chain and limited-stability infusion solutions within refrigeration-required formulations. These classifications help in understanding the market dynamics and targeting specific opportunities within the Veletri landscape.

Our latest 2026 market reports provide expanded strategic and visual intelligence with market attractiveness scoring and analysis, total addressable market (TAM) analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, key technologies and future trend analysis, together with updated graphics and tables.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 30,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.